NEW YORK (GenomeWeb News) – Sequenom has filed a Form S-3 with the US Securities and Exchange Commission covering the potential sale of securities worth $150 million.
Under the shelf registration, Sequenom may from time to time offer up to $150 million of common stock, preferred stock, debt securities, and warrants in any combination. The firm said that it may sell the securities directly to investors or to or through agents, underwriters, or dealers.